Limited biotech company Kaida BioPharma is working with Northway Biotech to make KAD101 which helps advance therapies for hormone-driven women’s cancers.

Kaida BioPharma and Northway Biotech have joined efforts to develop and advance KAD101 which is a drug in clinical development for cancer. Working with ImmunoGen is an important achievement for Kaida in its mission to give women specially targeted therapies against cancer.

KAD101 will be developed and manufactured at scale by Northway Biotech, a top CDMO. As part of the project, the team will develop the drug, adjust the production method and produce a drug substance batch that meets cGMP standards for Kaida’s upcoming Phase 1 clinical trial.

Craig Pierson, Kaida BioPharma’s founder and chairman, noted, “By partnering with a biotech, we move our lead program ahead and get closer to offering therapies for hormone-driven cancers.”

The biologic KAD101 works by targeting the prolactin receptor, stopping cancer cells from growing and triggering autophagy. It is first being tested for ovarian cancer and earlier studies have shown it can lower tumor size and is safe for patients.

Dr. Vladas Algirdas Bumelis, Northway Biotech CEO, says this achievement makes him proud and confirms the company’s focus on the next wave of biotechnology. The collaboration shows that biotech innovation is driving new therapies for cancer in women.